Suppression of 125I-vasoactive intestinal polypeptide binding sites in arteries of the hamster seminal vesicle following castration.

Barroso CP, Afonso F, Castro Caldas M, Pinho M, Mata L, Gulbenkian S

The Histochemical journal1 May 1999Cited by 2 (Europe PMC)

PMID10461861DOI10.1023/a:1003747716200PepBankPUB-10461861

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

01AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism
In the hamster seminal vesicle, 125I-VIP binding sites were found in the gland smooth muscle coat and in arterial smooth muscle.
In plain wordsIn hamsters, VIP-binding sites were found in the smooth muscle of the seminal vesicle gland and its arteries.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableLocation of 125I-VIP binding sites in seminal vesicle
Study
hamstern: not reported in source
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Source sentences
Summary
Our results show that, in the seminal vesicle, VIP-binding sites are localized in the gland smooth muscle coat and arterial smooth muscle.
1 context sentence(design, population, supporting numbers)
Summary · context
The presence and distribution of 125I-vasoactive intestinal polypeptide (VIP) binding sites in blood vessels supplying the hamster seminal vesicle was studied using a receptor autoradiographic technique before and following castration.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1046186101
02AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism
In hamsters, 15 days of castration abolished 125I-VIP binding to arterial smooth muscle of the seminal vesicle.
In plain wordsIn hamsters, 15 days after castration, VIP binding sites in the arteries of the seminal vesicle were gone.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Decrease125I-VIP binding to vascular smooth muscle after 15-day castration
Study
hamstern: not reported in source
Comparator
Intact animals
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Source sentences
Summary
A 15-day castration period abolishes 125I-VIP binding to vascular smooth muscle
1 context sentence(design, population, supporting numbers)
Summary · context
The presence and distribution of 125I-vasoactive intestinal polypeptide (VIP) binding sites in blood vessels supplying the hamster seminal vesicle was studied using a receptor autoradiographic technique before and following castration.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1046186102
03AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism
In hamsters, castration had no effect on 125I-VIP binding to the gland smooth muscle coat of the seminal vesicle.
In plain wordsIn hamsters, castration did not change VIP binding in the gland muscle coat of the seminal vesicle.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant change125I-VIP binding to gland smooth muscle coat after castration
Study
hamstern: not reported in source
Comparator
Intact animals
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Source sentences
Summary
but has no effect on 125I-VIP binding to the gland smooth muscle coat.
1 context sentence(design, population, supporting numbers)
Summary · context
The presence and distribution of 125I-vasoactive intestinal polypeptide (VIP) binding sites in blood vessels supplying the hamster seminal vesicle was studied using a receptor autoradiographic technique before and following castration.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1046186103
04AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism
In castrated hamsters, testosterone treatment restored 125I-VIP binding to arterial smooth muscle of the seminal vesicle, completely reversing the effect of castration.
In plain wordsIn castrated hamsters, testosterone brought back VIP binding in the arteries of the seminal vesicle.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Increase125I-VIP binding to vascular smooth muscle after testosterone treatment
Study
hamstern: not reported in source
Comparator
Castrated animals
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Source sentences
Summary
Treatment with testosterone restores 125I-VIP binding to the vascular smooth muscle, completely reversing the effect of castration.
1 context sentence(design, population, supporting numbers)
Summary · context
The presence and distribution of 125I-vasoactive intestinal polypeptide (VIP) binding sites in blood vessels supplying the hamster seminal vesicle was studied using a receptor autoradiographic technique before and following castration.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1046186104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.